EirGenix, Inc. engages in the research and development of biotechnology drugs. Its products and services include Trastuzumab Biosimilar, Pertuzumab Biosimilar, New Formulation, Antibody-Drug Conjugate, Bevacizumab Biosimilar, CRM197 Carrier Protein, and Biosimilar. The company was founded by Li Cheng Liu on December 21, 2012 and is headquartered in New Taipei, Taiwan.